DEF: Pulse Biosciences Schedules 2025 Annual Stockholder Meeting

Pulse Biosciences, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 9, 2025, to vote on director elections, auditor ratification, executive compensation, and other corporate matters.

Summary

• The Annual Meeting of Stockholders is scheduled for December 9, 2025, at 11:00 a.m. Eastern Time, and will be conducted virtually via live audio webcast.
• Stockholders will vote on the election of six directors, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025, a non-binding advisory vote on named executive officer compensation, and an advisory vote on the frequency of future executive compensation votes.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of Deloitte & Touche LLP, FOR the approval of executive compensation, and in favor of a 3-year frequency for future advisory votes on executive compensation.
• The record date for voting eligibility is October 22, 2025, with 67,757,578 shares of common stock outstanding and entitled to vote.
• The company reported a net loss of $53.585 million for the fiscal year ended December 31, 2024, following losses of $42.210 million in 2023 and $58.505 million in 2022.
• The Audit Committee currently consists of only two independent directors, which is below the Nasdaq minimum requirement of three, and the company is actively taking steps to regain compliance.

Sentiment

Score: 4

Explanation: The filing outlines routine annual meeting proposals and corporate governance updates. While there was a successful capital raise and some corporate objectives were met, the company continues to report net losses and has a notable compliance issue with its Audit Committee composition, alongside late insider trading filings. The ambitious performance targets for executive compensation suggest high future expectations, but current financial performance remains challenging.

Positives

• The company successfully closed its 2024 Rights Offering on July 3, 2024, raising $60 million in gross proceeds.
• Approximately $49.4 million in gross proceeds were received from exercises of the Rights Offering Warrants as of December 31, 2024.
• 88.88% of the company's 2024 corporate objectives were achieved, leading to cash bonus payouts in early 2025.
• The company has a Strategic Advisory Committee to foster cooperative strategic planning between the Board and management, leveraging Board member experience.
• An Incentive-Based Compensation Clawback Policy was adopted in 2023, complying with Dodd-Frank Act requirements, enhancing accountability.

Negatives

• The Audit Committee currently consists of only two independent directors, falling below Nasdaq's minimum requirement of three, resulting in non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).
• Several Section 16(a) reports (Form 4s) were filed late in 2024 by executive officers and directors, indicating compliance lapses.
• The company reported a net loss of $53.585 million in 2024, continuing a trend of net losses from previous fiscal years.

Risks

• Non-compliance with Nasdaq's audit committee composition requirements (minimum three independent directors) could lead to delisting action if not cured within the permitted period.
• The company has historically incurred significant net losses, with a $53.585 million net loss in 2024, indicating ongoing financial challenges.
• Executive compensation includes performance-based vesting tied to ambitious market capitalization and GAAP product revenue targets (e.g., up to $9.0 billion market cap and $500 million revenue for the CEO's full vesting), which may not be achieved.
• Robert W. Duggan, the majority stockholder, beneficially owns approximately 72.1% of the outstanding common stock, giving him substantial control over corporate decisions and potentially limiting the influence of other shareholders.

Future Outlook

The company's executive compensation program is designed to support long-term success, with performance-based equity awards tied to significant market capitalization and GAAP product revenue targets, indicating an expectation of substantial growth and profitability in the coming years. The Board intends to hold future say-on-pay votes in accordance with stockholder preference, recommending a three-year frequency.

Management Comments

• "We believe that good governance leads to high board effectiveness, promotes the long-term interests of our stockholders, strengthens the accountability of our Board of Directors and management, and improves our standing as a trusted member of the communities we serve."
• "Our Board of Directors is actively taking steps to regain compliance with Nasdaq's audit committee composition requirements."
• "We do not link our PEO and NEO compensation to the Company's financial and stock price performance. Instead we link a significant portion of their compensation to the achievement of key product development milestones."

Industry Context

The company operates in the medical technology and life sciences industry, as evidenced by the backgrounds of its directors and executives who have experience with companies like Boston Scientific, Edwards Lifesciences, Summit Therapeutics, and Pharmacyclics. The focus on product development milestones for executive compensation suggests a growth-stage company heavily invested in research, development, and commercialization within this sector. The D&O insurance challenges in 2022 might reflect broader market conditions for certain risk profiles in the industry.

Comparison to Industry Standards

• The company's Audit Committee composition, with only two independent directors, is currently below the Nasdaq standard of three, indicating a deviation from a key corporate governance benchmark.
• Executive compensation structures, particularly the performance-based equity awards for the CEO and CFO, are tied to ambitious market capitalization and revenue targets (e.g., up to $9.0 billion market cap and $500 million GAAP product revenue for the CEO; up to $5.0 billion market cap and $175 million GAAP product revenue for the CFO). These targets suggest a growth trajectory comparable to successful medical technology or biopharmaceutical companies, but the filing does not provide specific peer comparisons.
• The company's net losses over the past three years (2022-2024) are common for development-stage or growth-focused medical technology companies, but without specific industry benchmarks or comparable company financial performance, it is difficult to assess if these losses are within industry norms.

Management Changes

Corporate Governance

Related Party Transactions

• On May 31, 2023, the company paid a $1.0 million fee to Robert W. Duggan (Co-Chairman and majority stockholder) for personally providing indemnity coverage for director and officer liability for a one-year period (May 2022-May 2023).
• Robert W. Duggan, the company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering, which closed on July 3, 2024, raising $60 million.
• Messrs. Danahy and Barrett and Dr. Zanganeh (director and spouse of Mr. Duggan) also participated in the 2024 Rights Offering.
• Robert W. Duggan is the beneficial owner of approximately 72.1% of the outstanding common stock as of October 22, 2025.
• Mr. Duggan and Dr. Zanganeh (director) were married in December 2024, potentially creating deemed beneficial ownership for each other's holdings, though they disclaim voting/investment power over each other's shares.
• Three director nominees (Robert W. Duggan, Manmeet S. Soni, Mahkam Zanganeh) are officers of Summit Therapeutics Inc., a company controlled by Robert W. Duggan.

Stakeholder Impact

• Shareholders will vote on key corporate governance matters, including director elections, auditor ratification, and executive compensation. The Audit Committee non-compliance could impact investor confidence and potentially lead to delisting if not resolved. The significant ownership by Robert W. Duggan (72.1%) means he has substantial control over voting outcomes.
• Employees, particularly executives, are impacted by compensation programs designed to support long-term success, with bonuses tied to corporate objectives. The Clawback Policy impacts executive accountability.
• Management's compensation is tied to performance objectives, including ambitious market capitalization and revenue targets, incentivizing growth. Changes in executive roles (CEO, CFO, Controller) indicate strategic shifts.
• Regulatory Authorities (SEC, Nasdaq) are impacted by the company's compliance with filing requirements and listing rules, with current non-compliance regarding the Audit Committee composition requiring remediation.

Next Steps

• Hold the Annual Meeting of Stockholders on December 9, 2025, to vote on the proposed matters.
• Elect six directors to hold office until the 2026 annual meeting.
• Ratify the appointment of Deloitte & Touche LLP as independent auditors for fiscal year 2025.
• Address the non-compliance with Nasdaq's audit committee composition requirements by appointing a third independent director.
• File a Current Report on Form 8-K with the SEC after the Annual Meeting to announce final results.
• Prepare for the 2026 annual meeting, with stockholder proposal deadlines in January 2026.

Key Dates

Recommendation

The filing highlights a company in a transitional phase with new executive leadership and ambitious growth targets tied to executive compensation. While the successful capital raise and achievement of corporate objectives are positive, the persistent net losses and the current non-compliance with Nasdaq's Audit Committee requirements introduce significant uncertainty and risk. The high concentration of ownership by Robert W. Duggan (72.1%) also means that minority shareholders have limited influence. Investors should hold to observe how the company addresses its governance issues, progresses towards its ambitious financial targets, and manages its ongoing losses, before making further investment decisions.

Keywords

Pulse Biosciences, SEC Filing, DEF 14A, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Nasdaq Compliance, Equity Awards, Capital Raise, Medical Technology, Biotechnology